Brief: Cocrystal Pharma Reported New Broad-Spectrum Antiviral May Be Effective Against The H5n1 Avian Influenza Strain
20/06/2024 13:31
June 20 (Reuters) - Cocrystal Pharma Inc COCP.O :
* NEW BROAD-SPECTRUM ANTIVIRAL CURRENTLY IN A PHASE 2A
CLINICAL
TRIAL IN INFLUENZA A MAY BE EFFECTIVE AGAINST THE H5N1 AVIAN
INFLUENZA STRAIN IDENTIFIED IN HUMANS EXPOSED TO INFECTED DAIRY
COWS
Source text for Eikon: ID:nGNX1Vzt2R
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway